Experience

Securing $240 million and a jury verdict of willful infringement for Promptu in patent case against Comcast

Promptu Systems Corporation

US Synthetic secures ITC exclusion order barring polycrystalline diamond compacts (PDCs)

US Synthetic Corporation

Achieving precedent in preserving valuable patents for Lumify®

Eye Therapies, LLC

Finnegan client Maglula delivers crushing blow to Amazon’s arbitration practices over counterfeit products

Maglula, Ltd.

Finnegan secures $180M for CSRC in complex arbitrations

CSRC et al.

Protecting a blockbuster diabetes treatment for AstraZeneca

AstraZeneca AB

Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini

Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.

Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement

Eisai Co., Ltd.

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Intellia Therapeutics, Inc.

Recent Experience

Experience

AbbVie Inc., et al. v. Aurobindo Pharma U.S.A., Inc. et al.

AbbVie Inc., et al. v. Aurobindo Pharma U.S.A., Inc. et al.

3:24-cv-04603, D.N.J., Judges Quraishi, Day
3:24-cv-04662, D.N.J., Judges Quraishi, Day
3:24-cv-04852, D.N.J., Judges Quraishi, Day

Experience

Sandoz Inc. v. Boehringer Ingelheim International GmbH et al. Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.

PGR2022-00037, PTAB, Judges Newman, Obermann, Worth

Experience

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Intellia Therapeutics, Inc.

Experience

AbbVie Inc. et al v. Alvotech hf. AbbVie Inc. et al v. Alvotech hf.

1:21-cv-02258, 1:21-cv-02899, N.D. Ill., Judge Lee

Experience

Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc. Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc.

1:21-cv-01015, D. Del., Judges Hall, Williams

Experience

Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al. Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.

1:20-cv-01226, D. Del., Judge Andrews

Experience

Teva Pharmaceuticals International GmbH v. Eli Lilly and Company Teva Pharmaceuticals International GmbH v. Eli Lilly and Company

2020-1747, -1748, -1749, -1750, -1751, -1752, -1876, -1877, -1878, Fed. Cir.

Experience

Sandoz, Inc. et al v. Pharmacyclics LLC Sandoz, Inc. et al v. Pharmacyclics LLC

IPR2019-00865, PTAB, Judges Cotta, Snedden, Mitchell

Experience

Eli Lilly and Company v. Teva Pharmaceuticals International Eli Lilly and Company v. Teva Pharmaceuticals International

IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB

Experience

Finnegan client AbbVie secures non-institution decisions for Humira® patents Finnegan client AbbVie secures non-institution decisions for Humira® patents

IPR2018-01987, -01988, PTAB, Judges Ankenbrand, Harlow, Mitchell

Experience

AbbVie Inc. v. Sandoz Inc. AbbVie Inc. v. Sandoz Inc.

3:18-cv-12668, D.N.J., Judge Wolfson

Experience

Sandoz Inc. v. AbbVie Biotechnology, Ltd Sandoz Inc. v. AbbVie Biotechnology, Ltd

IPR2018-00002, -00156, IPR2017 -01824, -02106, -02105, PTAB, Judges Ankenbrand, Hulse, Mitchell

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.